论文部分内容阅读
四川抗菌素工业研究所继研究成功国产利福平和利福定(RFD)之后,又研究成功一种长效利福类药物,即利福喷丁(Cyclopentyl Rifamycin;DL-473),于1985年首次组织临床协作,以利福平为对照,观察其疗效及副作用。收治菌阳肺结核初治486例,复治74例,共560例。因药物副反应、不合作,并发其他疾病或原发耐药等退组初治43例,复治6例,共49例。满疗程初治443例,复治68例,共511例。其中男性319例,女性192
Following the successful research on domestic rifampicin and rifabutin (RFD), the Sichuan Institute of Antibiotics has also studied the successful long-acting niche drug, Cyclopentyl Rifamycin (DL-473), which was first introduced in 1985 Organization of clinical collaboration to rifampicin as a control, observe its efficacy and side effects. The initial treatment of colon cancer positive pulmonary tuberculosis 486 cases, 74 cases of retreatment, a total of 560 cases. Because of drug side effects, uncooperative, complicated by other diseases or primary drug resistance, such as the initial treatment of 43 cases of retreat, retreatment in 6 cases, a total of 49 cases. Treatment of 443 cases of initial treatment, rehabilitation of 68 cases, a total of 511 cases. There were 319 males and 192 females